Form D · Other

Embolx, Inc.

Sunnyvale, CA · CIK 0001601292

Offering snapshot reported Nov 1, 2022 · SEC filing

Reported sold
$1.63M
Offering amount: $1.63M
Investors reported
5
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 19, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 1, 2022Initial$1,629,000No comparison5SEC filing
May 27, 2014Initial$250,000No comparison1SEC filing
Mar 10, 2014Initial$250,000No comparison1SEC filing
Mar 10, 2014Amendment$662$0vs Feb 27, 20143SEC filing
Feb 27, 2014Initial$662No comparison3SEC filing

Offering details

Securities
Debt, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$130K (estimated)
Finders' fees
$0 (estimated)
Form D file number
021-463522

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Revere Securities LLC14178

Source: Form D, filed Nov 1, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Michael Allen Director, Executive
Tom Breton Executive
Robert J.J. De Neve Director, Executive
Norman Gitis Director
Frank Grillo Director
Michael Lin Executive
Paul Rogan Director
Tianhong Xu Director

Issuer details

Industry: Other (See others in industry)

Address:
530 Lakeside Drive Suite 200
Sunnyvale, CA, 94085